618 related articles for article (PubMed ID: 32329229)
1. Relationship between intestinal flora structure and metabolite analysis and immunotherapy efficacy in Chinese NSCLC patients.
Song P; Yang D; Wang H; Cui X; Si X; Zhang X; Zhang L
Thorac Cancer; 2020 Jun; 11(6):1621-1632. PubMed ID: 32329229
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy as second-line treatment and beyond for non-small cell lung cancer in a single center of China: Outcomes, toxicities, and clinical predictive factors from a real-world retrospective analysis.
Chen M; Li Q; Xu Y; Zhao J; Zhang L; Wei L; Zhong W; Wang M
Thorac Cancer; 2020 Jul; 11(7):1955-1962. PubMed ID: 32468726
[TBL] [Abstract][Full Text] [Related]
3. Association Between Clinical Tumor Burden and Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer.
Miyawaki T; Kenmotsu H; Mori K; Miyawaki E; Mamesaya N; Kawamura T; Kobayashi H; Omori S; Wakuda K; Ono A; Naito T; Murakami H; Harada H; Endo M; Ohde Y; Takahashi K; Takahashi T
Clin Lung Cancer; 2020 Sep; 21(5):e405-e414. PubMed ID: 32205040
[TBL] [Abstract][Full Text] [Related]
4. Predictive value of CD73 expression for the efficacy of immune checkpoint inhibitors in NSCLC.
Ishii H; Azuma K; Kawahara A; Kinoshita T; Matsuo N; Naito Y; Tokito T; Yamada K; Akiba J; Hoshino T
Thorac Cancer; 2020 Apr; 11(4):950-955. PubMed ID: 32061060
[TBL] [Abstract][Full Text] [Related]
5. Relationship between the efficacy of immunotherapy and characteristics of specific tumor mutation genes in non-small cell lung cancer patients.
Song P; Yang D; Wang H; Cui X; Si X; Zhang X; Zhang L
Thorac Cancer; 2020 Jun; 11(6):1647-1654. PubMed ID: 32342665
[TBL] [Abstract][Full Text] [Related]
6. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
7. Impact of Age on Outcomes with Immunotherapy in Patients with Non-Small Cell Lung Cancer.
Lichtenstein MRL; Nipp RD; Muzikansky A; Goodwin K; Anderson D; Newcomb RA; Gainor JF
J Thorac Oncol; 2019 Mar; 14(3):547-552. PubMed ID: 30476576
[TBL] [Abstract][Full Text] [Related]
8. A Minimum Of 100 Tumor Cells in a Single Biopsy Sample Is Required to Assess Programmed Cell Death Ligand 1 Expression in Predicting Patient Response to Nivolumab Treatment in Nonsquamous Non-Small Cell Lung Carcinoma.
Naito T; Udagawa H; Sato J; Horinouchi H; Murakami S; Goto Y; Kanda S; Fujiwara Y; Yamamoto N; Zenke Y; Kirita K; Matsumoto S; Yoh K; Niho S; Motoi N; Ohe Y; Ishii G; Goto K
J Thorac Oncol; 2019 Oct; 14(10):1818-1827. PubMed ID: 31260834
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients Aged ≥ 75 Years With Non-small-cell Lung Cancer (NSCLC): An Italian, Multicenter, Retrospective Study.
Luciani A; Marra A; Toschi L; Cortinovis D; Fava S; Filipazzi V; Tuzi A; Cerea G; Rossi S; Perfetti V; Rossi A; Giannetta L; Sala L; Finocchiaro G; Pizzutilo EG; Carelli S; Agustoni F; Cergnul M; Zonato S; Siena S; Bidoli P; Ferrari D
Clin Lung Cancer; 2020 Nov; 21(6):e567-e571. PubMed ID: 32591311
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non-small cell lung cancer (NSCLC) compared with chemotherapy (Quijote-CLICaP).
Ruiz-Patiño A; Arrieta O; Cardona AF; Martín C; Raez LE; Zatarain-Barrón ZL; Barrón F; Ricaurte L; Bravo-Garzón MA; Mas L; Corrales L; Rojas L; Lupinacci L; Perazzo F; Bas C; Carranza O; Puparelli C; Rizzo M; Ruiz R; Rolfo C; Archila P; Rodríguez J; Sotelo C; Vargas C; Carranza H; Otero J; Pino LE; Ortíz C; Laguado P; Rosell R;
Thorac Cancer; 2020 Feb; 11(2):353-361. PubMed ID: 31828967
[TBL] [Abstract][Full Text] [Related]
11. Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer.
Zhao S; Gao G; Li W; Li X; Zhao C; Jiang T; Jia Y; He Y; Li A; Su C; Ren S; Chen X; Zhou C
Lung Cancer; 2019 Apr; 130():10-17. PubMed ID: 30885328
[TBL] [Abstract][Full Text] [Related]
12. The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti-Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC.
Jin Y; Dong H; Xia L; Yang Y; Zhu Y; Shen Y; Zheng H; Yao C; Wang Y; Lu S
J Thorac Oncol; 2019 Aug; 14(8):1378-1389. PubMed ID: 31026576
[TBL] [Abstract][Full Text] [Related]
13. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.
Ricciuti B; Genova C; De Giglio A; Bassanelli M; Dal Bello MG; Metro G; Brambilla M; Baglivo S; Grossi F; Chiari R
J Cancer Res Clin Oncol; 2019 Feb; 145(2):479-485. PubMed ID: 30506406
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan.
Edahiro R; Kanazu M; Kurebe H; Mori M; Fujimoto D; Taniguchi Y; Suzuki H; Hirano K; Yokoyama T; Morita M; Fukuda Y; Uchida J; Makio T; Tamiya M
PLoS One; 2019; 14(7):e0220570. PubMed ID: 31365588
[TBL] [Abstract][Full Text] [Related]
15. The Impact of Beta Blockers on Survival Outcomes in Patients With Non-small-cell Lung Cancer Treated With Immune Checkpoint Inhibitors.
Oh MS; Guzner A; Wainwright DA; Mohindra NA; Chae YK; Behdad A; Villaflor VM
Clin Lung Cancer; 2021 Jan; 22(1):e57-e62. PubMed ID: 32900613
[TBL] [Abstract][Full Text] [Related]
16. [Therapeutic efficacy analysis of immunotherapy in small cell lung cancer].
Zhong J; Zheng QW; Zhao J; Wang ZP; Wu MN; Zhuo ML; Wang YY; Li JJ; Yang X; Chen HX; An TT
Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):771-776. PubMed ID: 32988161
[No Abstract] [Full Text] [Related]
17. Relationship between circulating tumor-associated autoantibodies and clinical outcomes in advanced-stage NSCLC patients receiving PD-1/-L1 directed immune checkpoint inhibition.
Tarhoni I; Wakefield CJ; Kollipara R; Fidler MJ; Batus M; Bonomi P; Borgia JA
J Immunol Methods; 2021 Mar; 490():112956. PubMed ID: 33434603
[TBL] [Abstract][Full Text] [Related]
18. Association between CD47 expression, clinical characteristics and prognosis in patients with advanced non-small cell lung cancer.
Arrieta O; Aviles-Salas A; Orozco-Morales M; Hernández-Pedro N; Cardona AF; Cabrera-Miranda L; Barrios-Bernal P; Soca-Chafre G; Cruz-Rico G; Peña-Torres ML; Moncada-Claudio G; Ramirez-Tirado LA
Cancer Med; 2020 Apr; 9(7):2390-2402. PubMed ID: 32043750
[TBL] [Abstract][Full Text] [Related]
19. Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors.
Hendriks LEL; Bootsma G; Mourlanette J; Henon C; Mezquita L; Ferrara R; Audigier-Valette C; Mazieres J; Lefebvre C; Duchemann B; Cousin S; le Pechoux C; Botticella A; De Ruysscher D; Dingemans AC; Besse B
Eur J Cancer; 2019 Jul; 116():182-189. PubMed ID: 31203193
[TBL] [Abstract][Full Text] [Related]
20. Tumor expression and usefulness as a biomarker of programmed death ligand 1 in advanced non-small cell lung cancer patients with preexisting interstitial lung disease.
Shibaki R; Murakami S; Matsumoto Y; Goto Y; Kanda S; Horinouchi H; Fujiwara Y; Yamamoto N; Motoi N; Kusumoto M; Yamamoto N; Ohe Y
Med Oncol; 2019 Apr; 36(6):49. PubMed ID: 31030326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]